Osteoarthritis goes beyond simple cartilage wear

Osteoarthritis affects more than 500 million people worldwide and deeply impacts their quality of life. Long considered a disease linked to cartilage wear, it is now recognized as a global joint disorder involving bones, ligaments, synovial membrane, and other tissues. Conventional treatments, such as anti-inflammatory drugs or corticosteroids, relieve symptoms but do not stop the progression of the disease or restore joint function.

The mechanisms behind osteoarthritis are complex and multifactorial. Aging, genetic predispositions, obesity, joint injuries, or chronic low-grade inflammation disrupt the balance between tissue destruction and repair. These imbalances lead to progressive cartilage degradation, changes in subchondral bone, synovial membrane inflammation, and ultimately, loss of mobility. Pain, often the first sign, can appear long before lesions are visible on imaging. It results from various mechanisms, including increased nerve sensitivity, local inflammation, and structural changes in the joint.

Recent advances have improved our understanding of the biological processes involved. For example, the Wnt signaling pathway, essential for maintaining cartilage balance, can be disrupted. When this pathway is overactive, it promotes the production of enzymes that degrade cartilage. Conversely, certain proteins like FrzB act as natural inhibitors of this pathway, thereby protecting the cartilage. Another key pathway, TGF-β, also plays a crucial role: its dysfunction accelerates cartilage degradation and promotes the formation of bony outgrowths called osteophytes, which further worsen symptoms.

Genes also influence susceptibility to osteoarthritis. Genetic variations can alter the response of joint tissues to mechanical stress or inflammation. For instance, mutations in genes such as Axin2 affect the regulation of the Wnt pathway, which can accelerate cartilage destruction. Additionally, hormonal factors, particularly those related to reproduction, appear to play a role in the development of the disease, although the exact mechanisms remain unclear.

Osteoarthritis does not manifest the same way in all patients. Several forms, or phenotypes, are distinguished based on the dominant mechanisms. Some patients exhibit marked inflammation of the synovial membrane, while others suffer primarily from metabolic imbalances, such as those seen in metabolic syndrome, or mechanical issues related to poor load distribution on the joint. Another form is associated with the accumulation of senescent cells—aging cells that secrete pro-inflammatory substances, worsening cartilage destruction. Identifying these different profiles allows for more targeted treatments tailored to each patient.

Current therapeutic approaches are exploring new avenues to address the root causes of the disease. Among them, regenerative therapies aim to repair damaged cartilage by stimulating the growth of new cells. Targeted anti-inflammatory agents, such as interleukin-1 or interleukin-6 inhibitors, seek to specifically block the molecules responsible for inflammation and cartilage degradation. Another innovative strategy involves eliminating senescent cells or modifying their behavior to reduce their harmful impact on the joint.

Treatments targeting subchondral bone are also under investigation. Drugs like strontium ranelate or denosumab act on bone remodeling to prevent cartilage degradation and relieve pain. Vitamin D and calcium, though less potent, also help maintain bone health and limit inflammation. At the same time, therapies such as hyaluronic acid or platelet-rich plasma are used to improve joint lubrication and promote tissue repair.

Inhibitors of metalloproteinases, enzymes that degrade cartilage, have shown promising results in the laboratory, but their clinical use is hindered by side effects and a lack of specificity. AMPK activators, a protein that regulates cellular metabolism, offer another interesting avenue. By stimulating this pathway, it is possible to reduce inflammation, improve mitochondrial function, and protect cartilage, as shown in studies with molecules like metformin.

Finally, precision medicine approaches, which tailor treatment to the patient’s genetic and molecular profile, could revolutionize osteoarthritis management. By combining biomarkers, advanced imaging techniques, and artificial intelligence algorithms, researchers hope to identify at-risk patients earlier and offer them personalized therapies. The goal is to move from a medicine that merely relieves symptoms to one capable of altering the course of the disease.

Legal Attributions

Study Citation

DOI: https://doi.org/10.1038/s41413-026-00540-6

Title: Novel therapeutic strategies for osteoarthritis: from mechanistic insights to precision medicine

Journal: Bone Research

Publisher: Springer Science and Business Media LLC

Authors: Muhammad Umar; Ziling Wang; Jingwen Li; Zhen Li; Gang Li; Liping Tong; Di Chen